surmount study tirzepatide Weight reduction with different doses of in 1 Obesity is associated with an

A prespecified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF DM trials demonstrated that significantly more patients treated with Wegovy 2.4 mg SC once weekly had an improvement of at least one in New York Heart Association (NYHA) functional class compared to those who received placebo (32.6% versus 21.5%, respectively

The greatest reduction was among those who took semaglutide or tirzepatide for three years

Compounded semaglutide and tirzepatide are not metabolized through the CYP3A4 pathway, so the grapefruit interaction does not apply directly

Depending on your plan, you may be eligible for partial reimbursement

During Tirzepatide treatment, you will receive regular injections as your provider prescribes

Anything that we can do to move that needle forward for these HFpEF patients is of high importance we need to look at those endpoints in another trial or other studies.